Get the Stockscreener App
1.60
1.23%
-0.02
Pre-market:
1.58
-0.02
-1.25%
Actinium Pharmaceuticals Inc stock is traded at $1.60, with a volume of 56,044.
It is down -1.23% in the last 24 hours and down -10.11% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.62
Open:
$1.63
24h Volume:
56,044
Relative Volume:
0.24
Market Cap:
$49.91M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-0.8743
EPS:
-1.83
Net Cash Flow:
$-47.49M
1W Performance:
-1.23%
1M Performance:
-10.11%
6M Performance:
-0.62%
1Y Performance:
-14.89%
1-Day Range:
$1.5911
$1.63
1-Week Range:
$1.56
$1.68
52-Week Range:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.60 | 50.54M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Actinium Pharmaceuticals Inc. stock trend forecast2025 Price Targets & Weekly High Momentum Picks - newser.com
Will Actinium Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Technical Overview & Safe Entry Trade Signal Reports - newser.com
Will Actinium Pharmaceuticals Inc. stock recover faster than marketWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Is Actinium Pharmaceuticals Inc. (Delaware) stock a contrarian opportunity2025 Trading Volume Trends & AI Driven Stock Price Forecasts - newser.com
Does Actinium Pharmaceuticals Inc. show high probability of reboundOil Prices & Capital Protection Trade Alerts - newser.com
Why Actinium Pharmaceuticals Inc. (7AY1) stock remains stableJuly 2025 Sentiment & Weekly Breakout Stock Alerts - newser.com
Why Actinium Pharmaceuticals Inc. (Delaware) stock stays undervaluedGlobal Markets & Entry Point Confirmation Signals - newser.com
How big funds are accumulating Actinium Pharmaceuticals Inc. (7AY1) stockJuly 2025 Earnings & Smart Investment Allocation Insights - newser.com
Is Actinium Pharmaceuticals Inc a good long term investmentTechnical Analysis Insights & Trusted Financial Advisors at No Cost - earlytimes.in
What drives Actinium Pharmaceuticals Inc 7AY1 stock priceVolume Analysis Techniques & Small Capital Wealth Plans - earlytimes.in
How geopolitical risks impact Actinium Pharmaceuticals Inc. (7AY1) stockMarket Movement Recap & AI Driven Stock Price Forecasts - newser.com
How to use Fibonacci retracement on Actinium Pharmaceuticals Inc.Inflation Watch & Consistent Return Investment Signals - newser.com
What drives Actinium Pharmaceuticals Inc stock priceContrarian Investment Ideas & Double Or Triple Capital - earlytimes.in
Short interest data insights for Actinium Pharmaceuticals Inc.2025 Analyst Calls & Smart Allocation Stock Reports - newser.com
Will Actinium Pharmaceuticals Inc. (Delaware) stock beat international competition2025 Price Momentum & Daily Market Momentum Tracking - newser.com
Exit strategy if you’re trapped in Actinium Pharmaceuticals Inc.Quarterly Portfolio Report & Reliable Breakout Forecasts - newser.com
How Actinium Pharmaceuticals Inc. (7AY1) stock performs in volatility spikesJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Published on: 2025-09-29 05:33:31 - newser.com
What analysts say about Actinium Pharmaceuticals Inc stockSector ETF Performance & Add These Before Everyone Else Does - earlytimes.in
Actinium Pharmaceuticals Inc Stock Analysis and ForecastVolume Profile Analysis & Market Volatility Strategies - Early Times
How to build a custom watchlist for Actinium Pharmaceuticals Inc.2025 Retail Activity & Real-Time Volume Triggers - newser.com
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):